Virotherapy

Oncolytic Virotherapy: Real Potential and Difficult Challenges

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Translation

The Translational Index Score: Improving the Entire Drug Development Cycle

Jo Varshney, Ph.D., D.V.M.

Failing Fast

Maximizing Resources and Potential for Success by Failing Fast

Nazar Elkarim, Ph.D.

Mikart

Expanded CDMO Capabilities

On the Journey to Support Drug Developers With End-to-End Outsourcing

Michelle Hall

Mikart

Preclinical Data

Transforming Drug Development with Frictionless Access to Real-Time Preclinical Data

Mark Mintz; Kristen M. Eisenhauer

Charles River Laboratories

Tissue Models

Developing a Robust In Vitro Intestinal Model for Preclinical Candidate Screening of GI Toxicity

Ron Laethem, Ph.D.

Altis Biosystems

Tissue Models

The Power of RepliGut In Vitro Intestinal Stem Cell Models

Bailey Zwarycz, Ph.D

Altis Biosystems

Preclinical

Increasing the Efficiency of Drug Development with Preclinical Testing Using Human Intestinal Stem Cells

Ron Laethem, Ph.D.

Altis Biosystems

Preclinical Data

Alligator Bioscience: New Preclinical Data Demonstrate Strong Anti-tumor Effects for the 4-1BB Antibody ATOR-1017

Nice Insight

Viral Vectors

Preclinical to Nearly Commercial Virus and Viral Vector Manufacturing

Jean Blehaut

Axplora

Preclinical Data

Encouraging Preclinical Data for Anticancer Drugs Reported by Verseon

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Preclinical Data

Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer

Syros Pharmaceuticals

Drug Discovery

Defense Department Commits $16 Million to Fight Bacterial Bioweapons

Steve Kuehn

Nice Insight